JP2011506476A5 - - Google Patents

Download PDF

Info

Publication number
JP2011506476A5
JP2011506476A5 JP2010538191A JP2010538191A JP2011506476A5 JP 2011506476 A5 JP2011506476 A5 JP 2011506476A5 JP 2010538191 A JP2010538191 A JP 2010538191A JP 2010538191 A JP2010538191 A JP 2010538191A JP 2011506476 A5 JP2011506476 A5 JP 2011506476A5
Authority
JP
Japan
Prior art keywords
region
sialic acid
terminal sialic
composition
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010538191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506476A (ja
Filing date
Publication date
Priority claimed from US11/957,015 external-priority patent/US20080206246A1/en
Application filed filed Critical
Publication of JP2011506476A publication Critical patent/JP2011506476A/ja
Publication of JP2011506476A5 publication Critical patent/JP2011506476A5/ja
Withdrawn legal-status Critical Current

Links

JP2010538191A 2007-12-14 2008-12-12 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法 Withdrawn JP2011506476A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/957,015 US20080206246A1 (en) 2006-04-05 2007-12-14 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
PCT/US2008/086622 WO2009079382A1 (en) 2007-12-14 2008-12-12 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods

Publications (2)

Publication Number Publication Date
JP2011506476A JP2011506476A (ja) 2011-03-03
JP2011506476A5 true JP2011506476A5 (enExample) 2012-02-02

Family

ID=40796321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538191A Withdrawn JP2011506476A (ja) 2007-12-14 2008-12-12 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法

Country Status (11)

Country Link
US (1) US20080206246A1 (enExample)
EP (1) EP2227255A4 (enExample)
JP (1) JP2011506476A (enExample)
CN (1) CN101896202A (enExample)
AU (1) AU2008338550A1 (enExample)
CA (1) CA2707304A1 (enExample)
EA (1) EA201070739A1 (enExample)
IL (1) IL206029A0 (enExample)
MX (1) MX2010006537A (enExample)
WO (1) WO2009079382A1 (enExample)
ZA (1) ZA201004045B (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2815768A3 (en) * 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2279410B1 (en) * 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
ES2615881T3 (es) 2009-05-07 2017-06-08 Stallergenes Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
KR101808751B1 (ko) 2009-11-13 2017-12-13 그리폴스 테라퓨틱스 인코포레이티드 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도
CN102947333A (zh) * 2010-05-07 2013-02-27 瑞士杰特贝林生物制品有限公司 抗体组合物
RU2604811C2 (ru) * 2010-05-27 2016-12-10 Мерк Шарп Энд Домэ Корп. Способ получения антител с улучшенными свойствами
AR085302A1 (es) * 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
JP2014517846A (ja) * 2011-05-25 2014-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 改善された特性を有するＦｃ含有ポリペプチドの製造方法
US20140286946A1 (en) * 2011-10-31 2014-09-25 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
EP2780463A4 (en) * 2011-11-18 2015-07-01 Merck Sharp & Dohme FC-CONTAINING POLYPEPTIDES WITH INCREASED INFLAMMATORY FEATURES AND INCREASED FCRN BINDING
CN104010659A (zh) 2011-12-19 2014-08-27 洛克菲勒大学 非唾液酸化的抗炎多肽
US12384848B2 (en) * 2011-12-19 2025-08-12 The Rockefeller University Anti-inflammatory polypeptides
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2012392760C1 (en) 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9587235B2 (en) 2013-03-15 2017-03-07 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057622A1 (en) 2013-10-16 2015-04-23 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2015106123A1 (en) * 2014-01-09 2015-07-16 The Johns Hopkins University Use of high flux scfa-derivatized monosaccharides in recombinant glycoprotein production
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
MY187045A (en) 2014-12-23 2021-08-27 Bristol Myers Squibb Co Antibodies to tigit
EA035412B1 (ru) 2015-05-29 2020-06-10 Бристол-Майерс Сквибб Компани Антитела к ox40 и их применение
US10479838B2 (en) 2015-06-29 2019-11-19 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
FR3038517B1 (fr) * 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
KR20180114223A (ko) 2016-03-04 2018-10-17 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CN110536694A (zh) 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
US20200299400A1 (en) 2017-05-25 2020-09-24 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
PE20201339A1 (es) 2017-12-19 2020-11-25 Univ Rockefeller Variantes de dominio de fc de igg humana con funcion efectora mejorada
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
US11505610B2 (en) 2018-04-06 2022-11-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
JP7490925B2 (ja) 2018-07-26 2024-05-28 エータイアー ファーマ， インコーポレイテッド Ｎｒｐ２関連疾患を治療するための組成物および方法
BR112021009111A2 (pt) 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos
JP2022513653A (ja) 2018-11-28 2022-02-09 ブリストル－マイヤーズ スクイブ カンパニー 修飾された重鎖定常領域を含む抗体
KR102549282B1 (ko) * 2019-11-18 2023-06-30 건국대학교 산학협력단 시알산화된 면역글로불린을 유효성분으로 포함하는 염증성 질환의 치료용 조성물
MX2022010826A (es) * 2020-03-05 2022-12-02 Momenta Pharmaceuticals Inc Métodos para elaborar inmunoglobulina hipersialilada.
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
WO2023034809A1 (en) 2021-08-30 2023-03-09 Lassen Therapeutics 1, Inc. Anti-il-11rα antibodies
CN118339189A (zh) * 2021-12-09 2024-07-12 上海宝济药业股份有限公司 具有改变的糖基化修饰的Fc多肽
JP2026503273A (ja) 2023-01-06 2026-01-28 ラッセン・セラピューティクス・インコーポレイテッド 抗ｉｌ－１８ｂｐ抗体
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2556219B1 (fr) * 1983-12-07 1987-06-26 Merieux Inst Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines
WO1992009293A1 (en) * 1990-11-23 1992-06-11 The General Hospital Corporation Inhibition of cell adhesion protein-carbohydrate interactions
CN100457914C (zh) * 1999-04-15 2009-02-04 荷兰克鲁塞尔公司 用编码腺病毒e1蛋白的序列在人体细胞中生产重组蛋白
DE19927835A1 (de) * 1999-06-18 2000-12-21 Clariant Gmbh Verwendung von verbesserten Cyanpigmenten in elektrophotographischen Tonern und Entwicklern, Pulverlacken und Ink-Jet-Tinten
US7064191B2 (en) * 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US7427469B2 (en) * 2002-11-05 2008-09-23 Institut Pasteur Method of treating cytomegalovirus with DC-SIGN blockers
US20070048740A1 (en) * 2003-02-14 2007-03-01 Research Association For Biotechnology Full-length cDNA
US7155641B2 (en) * 2003-05-15 2006-12-26 Microsoft Corporation System and method for monitoring the performance of a server
PT1692182E (pt) * 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
WO2005058244A2 (en) * 2003-12-15 2005-06-30 Alexion Pharmaceuticals, Inc. Novel anti-dc-sign antibodies
EP1937306B1 (en) * 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
WO2008057634A2 (en) * 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2455100A3 (en) * 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
EP2815768A3 (en) * 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2009087163A (ja) * 2007-10-01 2009-04-23 Brother Ind Ltd ジョブ実行装置及びジョブ実行方法

Similar Documents

Publication Publication Date Title
EP2953971B1 (en) Il-11r binding proteins and uses thereof
CN104144700B (zh) 抗CD1d的抗体
JP2008512988A5 (enExample)
KR20050033563A (ko) 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
CN111655717A (zh) IL-22 Fc融合蛋白及使用方法
KR20060117930A (ko) 인간 ｅｐｏ 미메틱 힌지 코어 미메티바디, 조성물, 방법및 용도
JP2011506476A (ja) 抗炎症性が促進しかつ細胞毒性が低減したポリペプチドおよび関連する方法
JP2018504911A (ja) 治療及び診断剤
US9731007B2 (en) Tumour necrosis factor receptor fusion proteins and methods of using the same
WO2010109010A1 (en) Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
CN120787235A (zh) Sars-cov-2棘蛋白特异性抗体及其用途
JP2022525754A5 (enExample)
JP2024503212A (ja) ネコ科動物抗体の定常領域における変異
JP2023551194A (ja) ウシ科動物抗体バリアント
JP2024505072A (ja) イヌ科動物抗体の定常領域における変異
JP2009508476A5 (enExample)
JP2023543262A (ja) イヌ科動物抗体バリアント
JP7173866B2 (ja) コンジュゲートされたｃ１エステラーゼインヒビター及びその使用
US20240076410A1 (en) Fc-engineered anti-human ige antibodies and methods of use
US20250230210A1 (en) Long-acting granulocyte macrophage-colony stimulating factor
JP6882440B2 (ja) 抗ｉｌ４−ｉｌ１３二重特異性抗体
TW202604967A (zh) 經修飾之Ｆｃ多肽
TW202227473A (zh) Ｇｌｐ１－ｇｃｇｒ抗體融合蛋白變體及包含其的組成物
WO2025049818A1 (en) Tnfr1 antagonists lacking agonist activity and uses thereof
TW202600604A (zh) Ghr激動型抗體及其應用